Skip to main content
. 2022 Aug 18;140(7):756–768. doi: 10.1182/blood.2021015328

Table 1.

Characteristics of patients at AML diagnosis

Characteristic DDX41MutGL AML DDX41WT AML, CT
All RL CT
No. of patients 191 105 86 1604
Male 144 (75%) 80 (76%) 64 (74%) 866 (54%)
Age, y 66 (59-70) 66 (59-70) 66 (61-69) 64 (54-69)
Hb, g/dL 10.4 (8.6-11.9) 10.3 (8.3-11.9) 10.7 (9.6-12.0) 9.8 (8.6-10.8)
WBC, ×109/L 1.99 (1.46-2.60) 1.90 (1.42-2.45) 2.00 (1.50-2.70) 7.9 (2.5-31.1)
ANC, ×109/L 0.62 (0.26-0.94) 0.62 (0.27-0.96) 0.60 (0.30-0.90) ND
Platelets, ×109/L 64 (39-110) 63 (37-85) 82 (42-171) 85 (42-174)
BM blasts, % 33 (24-47) 30 (23-47) 37 (28-47) 58 (35-80)
Trial, n (% in trial)
 ALFA-0701 NA NA 10 (5.4%) 176 (94.6%)
 ALFA-0702 NA NA 15 (2.7%) 531 (97.3%)
 ALFA-1200 NA NA 23 (5.3%) 408 (94.7%)
 ALFA-1401 NA NA 15 (7.6%) 182 (92.4%)
 LAM-SA 2007 NA NA 23 (6.9%) 307 (93.1%)
FAB classification
 Available 70 47 23 ND
 M0 7 (10%) 5 (11%) 2 (9%) ND
 M1 17 (25%) 14 (30%) 3 (13%) ND
 M2 42 (60%) 24 (51%) 18 (78%) ND
 M4 2 (3%) 2 (4%) 0 ND
 M5 1 (1%) 1 (2%) 0 ND
 M6 1 (1%) 1 (2%) 0 ND
Cytogenetics
 Available 156 80 76 1500
 Normal 117 (75%) 59 (74%) 58 (77%) 860 (57%)
 Complex 1 (1%) 1 (1%) 0 139 (9%)
 Trisomy 8 8 (5%) 6 (8%) 2 (3%) 158 (11%)
 Monosomy 5/del(5q) 3 (2%) 2 (3%) 1 (1%) 77 (5%)
 Monosomy 7 2 (1%) 1 (1%) 1 (1%) 65 (4%)
 Monosomy 17/del(17p) 0 0 0 58 (4%)
ELN-2017 risk
 Available 160 81 79 1545
 Favorable 9 (5%) 6 (7%) 3 (4%) 549 (36%)
 Intermediate 105 (66%) 51 (63%) 54 (68%) 427 (28%)
 Adverse 46 (29%) 24 (30%) 22 (28%) 569 (37%)

Data are expressed as median (IQR) unless otherwise indicated.

ANC, absolute neutrophil count; BM, bone marrow; FAB, French-American-British; Hb, hemoglobin; NA, not applicable; ND, not defined.